CN104491350A - 一种调节心脑血管健康和减少心脑血管疾病风险的保健品 - Google Patents
一种调节心脑血管健康和减少心脑血管疾病风险的保健品 Download PDFInfo
- Publication number
- CN104491350A CN104491350A CN201410827372.1A CN201410827372A CN104491350A CN 104491350 A CN104491350 A CN 104491350A CN 201410827372 A CN201410827372 A CN 201410827372A CN 104491350 A CN104491350 A CN 104491350A
- Authority
- CN
- China
- Prior art keywords
- cardiovascular
- health
- formula
- group
- product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000036541 health Effects 0.000 title claims abstract description 51
- 230000002526 effect on cardiovascular system Effects 0.000 title claims abstract description 44
- 208000024172 Cardiovascular disease Diseases 0.000 title claims abstract description 32
- 208000026106 cerebrovascular disease Diseases 0.000 title claims abstract description 31
- 230000001603 reducing effect Effects 0.000 title claims abstract description 10
- 230000001105 regulatory effect Effects 0.000 title abstract description 9
- 230000002490 cerebral effect Effects 0.000 title abstract 2
- 239000000284 extract Substances 0.000 claims abstract description 26
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims abstract description 15
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims abstract description 15
- 229930064664 L-arginine Natural products 0.000 claims abstract description 15
- 235000014852 L-arginine Nutrition 0.000 claims abstract description 15
- 235000013793 astaxanthin Nutrition 0.000 claims abstract description 15
- 239000001168 astaxanthin Substances 0.000 claims abstract description 15
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims abstract description 15
- 229940022405 astaxanthin Drugs 0.000 claims abstract description 15
- 239000002994 raw material Substances 0.000 claims description 13
- 239000000463 material Substances 0.000 claims description 7
- 235000013361 beverage Nutrition 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 3
- 239000000047 product Substances 0.000 abstract description 79
- 230000000694 effects Effects 0.000 abstract description 36
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 235000015872 dietary supplement Nutrition 0.000 abstract 1
- 235000020717 hawthorn extract Nutrition 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 38
- 238000009472 formulation Methods 0.000 description 35
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical group O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 32
- 150000002632 lipids Chemical class 0.000 description 29
- 235000013305 food Nutrition 0.000 description 26
- 241000699670 Mus sp. Species 0.000 description 25
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 24
- 210000004369 blood Anatomy 0.000 description 24
- 239000008280 blood Substances 0.000 description 24
- 229940039009 isoproterenol Drugs 0.000 description 20
- 238000012360 testing method Methods 0.000 description 20
- 241000700159 Rattus Species 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 19
- 238000000034 method Methods 0.000 description 19
- PLRACCBDVIHHLZ-UHFFFAOYSA-N 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Chemical compound C1N(C)CCC(C=2C=CC=CC=2)=C1 PLRACCBDVIHHLZ-UHFFFAOYSA-N 0.000 description 18
- 229960003753 nitric oxide Drugs 0.000 description 17
- 241001465754 Metazoa Species 0.000 description 15
- 239000005645 nematicide Substances 0.000 description 15
- 230000036772 blood pressure Effects 0.000 description 14
- -1 lignanoids Chemical class 0.000 description 14
- 230000008569 process Effects 0.000 description 14
- 101001135571 Mus musculus Tyrosine-protein phosphatase non-receptor type 2 Proteins 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 230000037396 body weight Effects 0.000 description 11
- 239000008103 glucose Substances 0.000 description 11
- 210000004072 lung Anatomy 0.000 description 11
- 230000001681 protective effect Effects 0.000 description 11
- 150000003254 radicals Chemical class 0.000 description 11
- 206010020772 Hypertension Diseases 0.000 description 10
- 229910052760 oxygen Inorganic materials 0.000 description 10
- 239000001301 oxygen Substances 0.000 description 10
- 206010033799 Paralysis Diseases 0.000 description 9
- 208000018737 Parkinson disease Diseases 0.000 description 9
- 230000006378 damage Effects 0.000 description 9
- 230000003203 everyday effect Effects 0.000 description 9
- 208000024827 Alzheimer disease Diseases 0.000 description 8
- 206010039966 Senile dementia Diseases 0.000 description 8
- 239000002671 adjuvant Substances 0.000 description 8
- 230000006399 behavior Effects 0.000 description 8
- 239000012153 distilled water Substances 0.000 description 8
- 238000003304 gavage Methods 0.000 description 8
- 239000000126 substance Substances 0.000 description 7
- 208000028389 Nerve injury Diseases 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 208000002173 dizziness Diseases 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 230000008764 nerve damage Effects 0.000 description 6
- 238000006722 reduction reaction Methods 0.000 description 6
- 201000006474 Brain Ischemia Diseases 0.000 description 5
- 206010008120 Cerebral ischaemia Diseases 0.000 description 5
- 208000031226 Hyperlipidaemia Diseases 0.000 description 5
- 206010008118 cerebral infarction Diseases 0.000 description 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000007760 free radical scavenging Effects 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 230000009261 transgenic effect Effects 0.000 description 5
- 230000003078 antioxidant effect Effects 0.000 description 4
- 210000001367 artery Anatomy 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 3
- 101150017888 Bcl2 gene Proteins 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 102000007330 LDL Lipoproteins Human genes 0.000 description 3
- 108010007622 LDL Lipoproteins Proteins 0.000 description 3
- 241000244206 Nematoda Species 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 206010016256 fatigue Diseases 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 201000001421 hyperglycemia Diseases 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 230000000291 postprandial effect Effects 0.000 description 3
- 230000003449 preventive effect Effects 0.000 description 3
- 230000002000 scavenging effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 2
- RPNUMPOLZDHAAY-UHFFFAOYSA-N Diethylenetriamine Chemical compound NCCNCCN RPNUMPOLZDHAAY-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 2
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000007472 neurodevelopment Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- PTSUYDXEEKDBQU-UHFFFAOYSA-N (6'-acetyloxy-5,6-diamino-3-oxospiro[2-benzofuran-1,9'-xanthene]-3'-yl) acetate Chemical compound O1C(=O)C2=CC(N)=C(N)C=C2C21C1=CC=C(OC(C)=O)C=C1OC1=CC(OC(=O)C)=CC=C21 PTSUYDXEEKDBQU-UHFFFAOYSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000238090 Astacus Species 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Natural products OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000911513 Homo sapiens Uncharacterized protein FAM215A Proteins 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000004852 Lung Injury Diseases 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- 206010043458 Thirst Diseases 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 206010069363 Traumatic lung injury Diseases 0.000 description 1
- 102100026728 Uncharacterized protein FAM215A Human genes 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000003293 cardioprotective effect Effects 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 239000000066 endothelium dependent relaxing factor Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 231100000515 lung injury Toxicity 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 231100000189 neurotoxic Toxicity 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- 210000002267 nissl body Anatomy 0.000 description 1
- 239000002840 nitric oxide donor Substances 0.000 description 1
- 206010029446 nocturia Diseases 0.000 description 1
- 229940023492 oral liquid product Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- CMFNMSMUKZHDEY-UHFFFAOYSA-M peroxynitrite Chemical compound [O-]ON=O CMFNMSMUKZHDEY-UHFFFAOYSA-M 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 238000007540 photo-reduction reaction Methods 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 150000005856 steroid saponins Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8964—Anemarrhena
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
对照 | 高脂食物 | 配方低剂量 | 配方高剂量 | |
体重/g | 22.8 | 47.6# | 43.8 | 41.5 |
肝脏系数 | 0.053 | 0.112# | 0.094* | 0.089* |
总胆固醇/mM | 1.95 | 6.32# | 5.73 | 5.32* |
甘油三酯/mM | 0.54 | 1.21# | 0.86* | 0.78* |
低密度脂蛋白/mM | 0.44 | 1.28# | 0.95* | 0.94* |
高密度脂蛋白/mM | 1.7 | 4.5# | 4.7 | 5.3* |
对照 | 糖尿病组 | 配方低剂量 | 配方高剂量 | |
空腹血糖/mM | 5.0 | 12.8# | 7.9* | 6.8* |
随机血糖/mM | 6.4 | 32.3# | 16.5* | 14.1* |
餐后血糖/mM | 6.5 | 23.8# | 15.1* | 13.6* |
对照 | 高血压组 | 配方低剂量 | 配方高剂量 | |
血压/mmHg | 112 | 190 | 175 | 160 |
参数 | 对照组 | ISO组 | ISO+配方组 |
体重(g) | 27.40±0.74 | 27.99±1.02 | 27.16±0.71 |
心脏重量(g) | 0.1018±0.0044 | 0.1582±0.0016* | 0.1114±0.0033# |
肺脏重量(g) | 0.1482±0.0073 | 0.1722±0.0049* | 0.1510±0.0051# |
心脏/体重(mg/g) | 3.74±0.23 | 5.67±0.15* | 4.11±0.14# |
肺脏/体重(mg/g) | 5.40±0.16 | 6.19±0.33* | 5.58±0.27 |
心脏射血分数(%) | 67.5±0.88 | 48.3±0.36* | 59.4±0.98# |
对照 | 配方低剂量 | 配方高剂量 | |
神经损伤分数 | 2.9 | 2.5 | 1.8* |
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410827372.1A CN104491350B (zh) | 2014-12-27 | 2014-12-27 | 一种调节心脑血管健康和减少心脑血管疾病风险的保健品 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410827372.1A CN104491350B (zh) | 2014-12-27 | 2014-12-27 | 一种调节心脑血管健康和减少心脑血管疾病风险的保健品 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104491350A true CN104491350A (zh) | 2015-04-08 |
CN104491350B CN104491350B (zh) | 2017-11-07 |
Family
ID=52932864
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410827372.1A Active CN104491350B (zh) | 2014-12-27 | 2014-12-27 | 一种调节心脑血管健康和减少心脑血管疾病风险的保健品 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104491350B (zh) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104921244A (zh) * | 2015-07-05 | 2015-09-23 | 青岛浩大海洋保健食品有限公司 | 一种具有调节血脂功效的虾青素保健饮料 |
CN104997119A (zh) * | 2015-07-05 | 2015-10-28 | 青岛浩大海洋保健食品有限公司 | 一种具有降血糖功效的虾青素保健饮料 |
CN105011277A (zh) * | 2015-07-05 | 2015-11-04 | 青岛浩大海洋保健食品有限公司 | 一种具有调节血脂功效的海洋功能性保健饮料 |
CN106360666A (zh) * | 2016-08-22 | 2017-02-01 | 张标 | 一种含有虾青素的抗氧化营养保健品 |
CN107397104A (zh) * | 2017-07-21 | 2017-11-28 | 何玉松 | 一种大麦嫩苗粉固体饮料及其制备方法 |
CN107455739A (zh) * | 2017-07-21 | 2017-12-12 | 何玉松 | 一种降三高保健营养粉 |
CN108685091A (zh) * | 2017-04-11 | 2018-10-23 | 郑州桂仁医药科技有限公司 | 基于虾青素且预防心脑血管疾病的保健片剂及其制备方法 |
CN109645494A (zh) * | 2019-01-23 | 2019-04-19 | 四川治宇东盟贸易有限责任公司 | 改善人体机能和预防心脑血管疾病的组合物及制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101780181A (zh) * | 2009-01-16 | 2010-07-21 | 陈祥槐 | 一氧化氮自由基保健品 |
-
2014
- 2014-12-27 CN CN201410827372.1A patent/CN104491350B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101780181A (zh) * | 2009-01-16 | 2010-07-21 | 陈祥槐 | 一氧化氮自由基保健品 |
Non-Patent Citations (4)
Title |
---|
FREDRIC J. PASHKOW: "Astaxanthin: A Novel Potential Treatment for Oxidative Stress and Inflammation in Cardiovascular Disease", 《THE AMERICAN JOURNAL OF CARDIOLOGY》 * |
唐利华等: "L-精氨酸/一氧化氮信号通路研究进展", 《饲料研究》 * |
王月刚: "山楂对心血管***的药理作用研究", 《中医药信息》 * |
高帅: "知母活性成分提取工艺优化及降糖活性研究", 《中国优秀硕士学位论文全文数据库 医生卫生科技辑》 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104921244A (zh) * | 2015-07-05 | 2015-09-23 | 青岛浩大海洋保健食品有限公司 | 一种具有调节血脂功效的虾青素保健饮料 |
CN104997119A (zh) * | 2015-07-05 | 2015-10-28 | 青岛浩大海洋保健食品有限公司 | 一种具有降血糖功效的虾青素保健饮料 |
CN105011277A (zh) * | 2015-07-05 | 2015-11-04 | 青岛浩大海洋保健食品有限公司 | 一种具有调节血脂功效的海洋功能性保健饮料 |
CN106360666A (zh) * | 2016-08-22 | 2017-02-01 | 张标 | 一种含有虾青素的抗氧化营养保健品 |
CN108685091A (zh) * | 2017-04-11 | 2018-10-23 | 郑州桂仁医药科技有限公司 | 基于虾青素且预防心脑血管疾病的保健片剂及其制备方法 |
CN107397104A (zh) * | 2017-07-21 | 2017-11-28 | 何玉松 | 一种大麦嫩苗粉固体饮料及其制备方法 |
CN107455739A (zh) * | 2017-07-21 | 2017-12-12 | 何玉松 | 一种降三高保健营养粉 |
CN109645494A (zh) * | 2019-01-23 | 2019-04-19 | 四川治宇东盟贸易有限责任公司 | 改善人体机能和预防心脑血管疾病的组合物及制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN104491350B (zh) | 2017-11-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104491350A (zh) | 一种调节心脑血管健康和减少心脑血管疾病风险的保健品 | |
CN102048224B (zh) | 一种祛黄褐斑美容养颜红枣保健饮料及其生产工艺 | |
CN101011561A (zh) | 黄连温胆汤现代中药口服制剂及其生产方法 | |
CN104225456B (zh) | 一种降血糖的药物组合物 | |
KR101930483B1 (ko) | 발효 청미래덩굴 잎 및 이의 추출물 | |
CN107080250A (zh) | 一种辅助降血糖的组合物、饮料及其制备方法 | |
CN107455625A (zh) | 一种具有抗疲劳减肥功能的植物营养素饮料及其制备工艺 | |
CN106244371A (zh) | 一种降血糖黄精葡萄保健酒及其生产工艺 | |
KR101771695B1 (ko) | 스피루리나 추출물을 유효성분으로 함유하는 비만 예방 및 치료용 약학적 조성물 | |
CN105341893A (zh) | 一种辅助降血糖的组合物及应用 | |
CN107006856A (zh) | 一种增强耐力、提高抗缺氧耐受力营养剂及其制备方法 | |
KR101695207B1 (ko) | 상륙 추출물을 유효성분으로 함유하는 항암제 유발 말초신경병증 예방 또는 치료용 약학적 조성물 | |
EP2260855A1 (en) | Composition containing aqueous extract of ashwaganda leaves as the active ingredient and method of producing the same | |
KR101394358B1 (ko) | 숙취 해소용 조성물 | |
CN103977390B (zh) | 一种生姜洋葱药酒组合物的制备方法及其用途 | |
KR101034986B1 (ko) | 혼합 생약추출물을 유효성분으로 함유하는 숙취해소용 조성물 | |
CN108567914A (zh) | 一种具有改善睡眠作用的中药制剂及其制备方法和应用 | |
CN108077485A (zh) | 一种青钱柳凉茶及其制备方法 | |
CN104256618B (zh) | 一种降血糖的食品、保健品或药物组合物 | |
CN114145374A (zh) | 一种黄芪玉须复合茶及其制备方法和应用 | |
CN104013696B (zh) | 一种防治代谢综合征的植物药组合物及其应用 | |
KR20140080289A (ko) | 산화적 뇌손상 및 뇌기능 장애의 예방 또는 치료용 조성물 및 이의 제조방법 | |
CN104815140A (zh) | 一种预防或/和治疗糖尿病的组合物及其制备方法 | |
CN108236714B (zh) | 缓解体力疲劳和辅助降血脂的组合物及其软胶囊 | |
CN115154506B (zh) | 一种改善缺氧应激状态的组合物及其制备方法及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20170519 Address after: Qing Ping Road Qingpu District Xujing town Shanghai City Luzhou 201700 No. 2008 floor 10 room 1025 Applicant after: SHANGHAI NO-TOP BIOTECHNOLOGY CO., LTD. Address before: 200030 No. 1088 Qinzhou North Road, Shanghai, Xuhui District Applicant before: Zhang Biao |
|
CB03 | Change of inventor or designer information |
Inventor after: Zhang Biao Inventor after: Zhao Baolu Inventor after: Mu Lade Inventor after: Zhang Biao Zhao Baolu Muradegeorge Smoot Inventor before: Zhao Baolu Inventor before: Zhang Biao |
|
CB03 | Change of inventor or designer information | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20190117 Address after: 511442 Room 602, 4 Building, 383 North Panyu Avenue, Nancun Town, Panyu District, Guangzhou City, Guangdong Province Patentee after: Guangzhou Sansan Medical Biotechnology Co., Ltd. Address before: Room 1025, 10th floor, 2008 Luqingping Road, Xujing Town, Qingpu District, Shanghai Patentee before: SHANGHAI NO-TOP BIOTECHNOLOGY CO., LTD. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20190124 Address after: 511442 Room 602, 4 Building, 383 North Panyu Avenue, Nancun Town, Panyu District, Guangzhou City, Guangdong Province Patentee after: Guangzhou Sansan Medical Biotechnology Co., Ltd. Address before: Room 1025, 10th floor, 2008 Shanghai Qingping Highway, Xujie Town, Qingpu District, Shanghai Patentee before: SHANGHAI NO-TOP BIOTECHNOLOGY CO., LTD. |